Coreline Soft, a South Korean medical AI company that trades on the KOSDAQ exchange under ticker 384470, and INFINITT North America announced on August 21 the deployment of a chest CT-based AI reading workflow at St. Joseph’s Health, an academic hospital system in Paterson, New Jersey. It is the second major North American deployment for the two companies, following an earlier implementation at ImageCare Radiology, and the release itself does not mention that Coreline Soft is publicly traded, a detail worth noting for readers evaluating this as more than a private vendor announcement.

How the Workflow Works

The new workflow runs on Coreline Soft’s AVIEW platform, integrated directly into St. Joseph’s existing INFINITT picture archiving and communication system, or PACS, the software hospitals use to store and view medical images. Rather than requiring radiologists to open a separate application, the AI analysis appears as structured results inside the same system they already use day to day. The initial rollout focuses on chest CT scans performed for lung cancer screening, where the AI pre-analyzes images to help identify and quantify findings such as lung nodules before a radiologist reviews the case.

What the AI Is Meant to Catch

Chest CT scans are typically read with a specific clinical question in mind, but the same scan often contains other potentially useful information, including early signs of lung cancer, emphysema, or cardiovascular risk, that may not be the focus of the original reason for the scan. Coreline Soft says its platform helps radiologists systematically review those additional findings and compare them against prior scans over time, an approach known as longitudinal assessment that can help distinguish a finding that is stable from one that is changing in a way that warrants follow-up. Whether this actually improves diagnostic outcomes at St. Joseph’s has not been measured or reported in this release; the claims describe the tool’s intended function rather than a demonstrated clinical result.

What the Companies Are Saying

INFINITT North America CEO and President David Smarro said the deployment reflects a shared commitment to high-quality care with St. Joseph’s Health and described the goal as making sophisticated AI analysis accessible in a way that feels natural to radiologists. A Coreline Soft North America spokesperson said the value of medical AI lies not just in detecting lesions but in weaving AI into how clinicians already work. Both statements describe the companies’ stated goals for the technology rather than independently measured outcomes for patients or the hospital.

From Outpatient Practice to Hospital System

The move from ImageCare Radiology, a high-volume outpatient radiology practice, to St. Joseph’s, a hospital-based academic health system, matters because the two settings have different workflows, patient populations, and IT environments. Successfully adapting the same PACS-integrated approach across both suggests the companies are building a repeatable deployment model rather than a one-off custom project, which is relevant to how quickly this kind of technology might scale to additional hospitals if the approach continues to work as intended.

Regulatory and Corporate Background

Coreline Soft says it holds 12 FDA 510(k) clearances for its AI products, a specific and checkable regulatory claim, though the release does not specify which clearances cover the exact features being used in this deployment. INFINITT North America operates as a subsidiary of INFINITT Healthcare, a global medical imaging and IT company, and is headquartered in Phillipsburg, New Jersey. St. Joseph’s Health describes itself as a teaching affiliate of New York Medical College that has served Northern New Jersey for more than 150 years.

Part of a Broader Partnership Push

This deployment is also one of several recent Coreline Soft partnership announcements. The company has separately said it intends to collaborate with Optellum across multiple disease areas in the lung cancer pathway, and previously announced a partnership with Mint Medical focused on AI-enabled lung cancer screening. Taken together, these announcements point to a company actively building out distribution and integration partnerships across the imaging AI ecosystem, rather than relying on a single deal to carry its commercial story.

What’s Next

For investors specifically, it is worth noting that Coreline Soft is a small, thinly capitalized public company; public market data shows the company posting modest revenue in the low single-digit millions of dollars alongside ongoing net losses in recent periods, typical of an early-stage medical AI firm still building out its commercial base. A single hospital deployment, even a meaningful one, is unlikely to be financially material to the company on its own, and no financial terms of the St. Joseph’s agreement were disclosed. Coreline Soft and INFINITT North America say they plan to expand this deployment model to additional institutions across North America, continuing to refine elements like PACS integration and structured reporting as they do. This article covers a technology deployment and is not an investment recommendation.

Sources

Coreline Soft and INFINITT North America Deploy Chest CT-Based AI Reading Workflow at St. Joseph’s Health, PRNewswire, August 21, 2026.

Coreline Soft Co., Ltd. (KOSDAQ: 384470) financial overview, cited for background on Coreline Soft’s public listing and financial profile.

Editorial Disclosure

This article is based on a press release issued by Coreline Soft on August 21, 2026, distributed via PRNewswire, with public-company background drawn from independent financial data sources cited above rather than from the press release itself, which did not disclose Coreline Soft’s public listing. Coreline Soft trades on the KOSDAQ exchange under ticker 384470; INFINITT North America and St. Joseph’s Health are not publicly traded. BioTech Stocks Daily was not compensated for this coverage. Statements regarding the clinical benefits of the AI workflow are the companies’ stated goals rather than independently measured outcomes. This article is for informational and educational purposes only, does not constitute investment advice, and is not medical advice. See our full DISCLAIMER.